Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q3 2024 Earnings Presentation
19 slides from Inovio Pharmaceuticals's earnings presentation, Nov 14, 2024
Slide 1: Third Quarter 2024 Financial Results
Third Quarter 2024 Financial Results November 14, 2024 :INO 1
Slide 2: Agenda
Agenda • Introduction ◦ Thomas Hong, Manager, IR • CEO Perspective & Corporate Progress ◦ Jacqueline Shea, PhD, President & Chief Executive Officer • INO-3107 Update ◦ Michael Sumner, MBBS, MBA, Chief Medical Officer ◦ Steve Egge, Chief Commercial Officer • Financial Results ◦ Peter Kies, Chief Fina
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,”” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding
Slide 4: CEO Perspective & Corporate Progress
CEO Perspective & Corporate Progress 4
Slide 5: INOVIO continues to make progress on key objectives
• Prepare for Commercialization of INO-3107 – New immunology data presented at scientific conferences – Positive pre-BLA meeting with FDA in August INOVIO continues ◦ All modules, other than device-related, expected to be complete by YE24 to make progress ◦ Resolving manufacturing issue for single u
Slide 6: Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis (RRP) • Rare disease characterized by small, wart-like growths (papillomas) in the respiratory tract ◦ Can form anywhere but primarily affect larynx & vocal cords ◦ Can cause difficulty speaking or complete voice loss, difficulty swallowing, shortness of breath a
Slide 7: Potential Novel, Effective Non-Surgical Treatment for RRP
Potential Novel, Effective Non-Surgical Treatment for RRP Before INO-3107 After INO-3107 INO-3107 is a DNA medicine that generates antigen- specific cytotoxic CD8 T cells targeting both HPV-6 and HPV-11 with the potential to treat the underlying infection in patients with RRP ◦ Compelling combinatio
Slide 8: Promising Clinical Benefit Observed in RRP Patients
Promising Clinical Benefit Observed in RRP Patients RRP-001 Study Parameter Complete Response (CR): no surgeries during a 52- week treatment phase Partial Response (PR): a ≥ 50% reduction and less than 100% in surgeries compared to previous year Overall Response Rate (ORR)=CR+PR: Patients with compl
Slide 9: Overall safety (primary endpoint)
Overall safety (primary endpoint) Adverse Event Patients (N=32), n (%) Any pretreatment AE 5 (15.6) Any TEAE 20 (62.5) Any treatment-related TEAE 13 (40.6) Any SAE 2 (6.3) Any treatment-related SAE 0 (0) Any TEAE by severity Any Grade 1 15 (46.9) Any Grade 2 9 (28.1) Any Grade 3 4 (12.5) Any treatme
Slide 10: Proposed Mechanism of Action
Proposed Mechanism of Action Induce HPV antigen-specific T cell responses in blood, travel to/infiltrate papilloma/airway tissue, eradicate HPV infected cells to reduce/eliminate need for surgery CIRCULATION Pre-existing Expansion of pre-existing T cells and T cells in blood Treatment with induction
Slide 11: New Immunology Data
New Immunology Data Presented at AACR (October 19) & IPVC (November 14) • INOVIO conducted an immunology assessment of INO-3107 – 32 patients in Phase 1/2 trial (RRP-001) – Blood samples taken throughout trial. Paired airway tissue biopsies taken prior to treatment and at trial end assessed for immu
Slide 12: Key Takeaways: Immunological Evaluation of INO-3107
Key Takeaways: Immunological Evaluation of INO-3107 Create an immune Right kind of immune T cells get where they need response in responses generated to to go – into the papilloma/airway tissue fight HPV in all 32 patients papilloma/airway tissue that reduces or eliminates the need for surgery Immun
Slide 13: Why is the immunology data important for INO-3107?
Why is the immunology data important for INO-3107? • Supports mechanism of action and is an important component of regulatory filings • Confirms the targeting of HPV-6 and HPV-11, the strains that cause disease • Confirms the expansion of existing populations of T cells and induction of new T cells
Slide 14: INO-3107: Advancing Plans to be Launch Ready by YE2025
INO-3107: Advancing Plans to be Launch Ready by YE2025* • Refining go-to-market strategy: focused on patient needs • Conducting additional market research to develop thorough market understanding: every surgery matters • Driving key strategic choices: – Pricing and access – Channel strategy – Target
Slide 15: Financial Update
Financial Update 15
Slide 16: Ongoing Commitment to Financial Discipline
Ongoing Commitment to Financial Discipline Three Months Three Months • $84.8M in cash, cash equivalents Ended Sept 30, Ended Sept 30, and short-term investments at 2024 2023 % (unaudited) (unaudited) Change September 30, 2024 Operating expenses $27.3 $35.9 (24.0%) • No debt Net loss ($25.2) ($33.9)
Slide 17: Q&A
Q&A 17
Slide 18: Upcoming Milestones
Upcoming Milestones 2024 2025 • INO-3107: • INO-3107: o Present new immunology data - Submit IND o Announce results from durability study - Initiate confirmatory trial • INO-4201 (Ebola booster): Submit Phase 2 trial - Submit BLA design based on FDA feedback - Advance commercial activities to be • F
Slide 19: Thank you.
Thank you. 19
Inovio Pharmaceuticals — Q3 2024 Earnings Presentation on 6ix